Formulation strategies for sustained release of proteins

Therapeutic Delivery

Volumn 1, Issue 3, 2010, Pages 457-479

  Lewis, Andrew L ^a   Illum, Lisbeth ^a  

^a Critical Pharmaceuticals Limited   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYL 2 PYRROLIDINONE; ANGIOPEPTIN; AUTOGEL; BUPIVACAINE; CYCLODEXTRIN; DOXYCYCLINE HYCLATE; GOSERELIN; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH HORMONE; HUMAN GROWTH HORMONE; INSULIN; INTERLEUKIN 2; ISONIAZID; LEUPRORELIN; MACROGOL; MICROSPHERE; OCTREOTIDE; PACLITAXEL; POLOXAMER; POLYCAPROLACTONE; POLYGLACTIN; POLYLACTIC ACID; POLYSACCHARIDE; RECOMBINANT ALPHA2B INTERFERON; RIFAMPICIN; RISPERIDONE; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE; SUCROSE ACETATE ISOBUTYRATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; WATER OIL CREAM;

ACROMEGALY; AREA UNDER THE CURVE; BIOCOMPATIBILITY; BIODEGRADABLE IMPLANT; BREAST CANCER; COACERVATION; CYTOKINE RELEASE; DIABETES MELLITUS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG IMPLANT; DRUG MANUFACTURE; DRUG PENETRATION; DRUG SOLUBILITY; DRUG TOLERABILITY; ENDOMETRIOSIS; GELATION; GROWTH HORMONE DEFICIENCY; HEPATITIS C; HIGH TEMPERATURE PROCEDURES; HUMAN; MAXIMUM PLASMA CONCENTRATION; MICROENCAPSULATION; NANOEMULSION; NANOENCAPSULATION; NEUROENDOCRINE TUMOR; NONHUMAN; PERIODONTAL DISEASE; POSTOPERATIVE PAIN; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SINGLE DRUG DOSE; SKIN ALLERGY; SUPERCRITICAL FLUID; SUSTAINED RELEASE FORMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

EID: 79954486354     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.10.17     Document Type: Review

References (150)

1. World Health Organisation. Adherence to Long-term Therapies -Evidence for Action. ISBN: 9241545992 (2003).
2. Folkman J, Long DM. The use of silicone rubber as a carrier for prolonged drug therapy. Surg. Res. 4, 139-142 (1964).
3. Heller J. Patient-friendly bioerodible drug delivery systems. J. Control. Release 133, 88-89 (2009).
4. Kosobucki BR, Freeman WR, Cheng L. Photographic estimation of the duration of high dose intravitreal triamcinolone in the vitrectomised eye. Br. J. Ophthalmol. 90, 705-708 (2006). (Pubitemid 43835485)
5. Govardhan C, Khalaf N, Jung CW, et al. Novel long acting crystal formulation of human growth hormone. Pharm. Res. 22(9), 1461-1470 (2005). (Pubitemid 41215886)
6. Kim SJ, Hahn SK, Kim MJ, et al. Development of a novel sustained release formulation of recombinant human growth hormone using sodium hyaluronate microparticles. J. Control. Release 104, 323-335 (2005).
7. Hahn SK, Kim SJ, Kim MJ, Kim DH. Characterisation and in vivo study of sustained release formulation of human growth hormone using sodium hyaluronate. Pharm. Res. 21(8), 1374-1381 (2004). (Pubitemid 39149651)
8. Bidlingmaier M, Kim J, Savoy C, et al. Comparative pharmacokinetics and pharmacodynamics of a new sustained release growth hormone, LB03002, versus daily GH in adults with GH deficiency. J. Clin. Endo. Met. 91(8), 2926-2930 (2006). (Pubitemid 44271737)
9. Peter F, Savoy C, Ji HJ, et al. Pharmacokinetic and pharmacodynamic profile of a new sustained release GH formulation, LB03002, in children with GH deficiency. Eur. J. Endo. 160, 349-355 (2009).
10. Chang TMS. Semipermeable microcapsules. Science 146 (3643), 524-525 (1964).
11. Chang TMS, Poznansky MJ. Semipermeable microcapsules containing catalase for enzyme replacement in acatalasaemic mice. Nature 218, 243-245 (1968).
12. Folkman J, Langer R. Polymers for the sustained release of proteins and other macromolecules. Nature 263, 797-800 (1976).
13. Anderson JM, Shive MS. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv. Drug Delivery Rev. 28, 5-24 (1997). (Pubitemid 27497671)
14. Blasi P, D'Souza SS, Selmin F, DeLuca PP. Plasticizing effect of water on poly(lactide-co-glycolide). J. Control. Release 108, 1-9 (2005). (Pubitemid 41476669)
15. Tracey MA, Ward KL, Firouzabadian L, et al. Factors affecting the degradation rate of PLGA microspheres in vivo and in vitro. Biomaterials 20, 1057-1062 (1999). (Pubitemid 29229474)
16. Passerini N, Craig DQM. An investigation into the effects of residual water on the glass transition temperature of polylactide microspheres using modulated DSC. J. Control. Release 73, 111-115 (2001). (Pubitemid 32406105)
17. Wang J, Wang BM, Shwendeman SP. Characterisation of the initial burst release of a model peptide from poly(d,l-lactide-co-glycolide) microspheres. J. Control. Release 82, 289-307 (2002). (Pubitemid 34880185)
18. Fu K, Pack DW, Klibanov AM, Langer R. Visual evidence of acidic environment within degrading poly(lactic-co-glycolic acid) (PLGA) microspheres. Pharm. Res. 17(1), 100-106 (2000). (Pubitemid 30121107)
19. Ding AG, Schwendeman SP. Acidic microclimate pH distribution in PLGA microspheres monitored by confocal laser scanning microscopy. Pharm. Res. 25(9), 2041-2052 (2008).
20. Li L, Schwendeman SP. Mapping microclimate pH in PLGA microspheres. J. Control. Release 101, 163-173 (2005).
21. Ding AG, Shenderova A, Schwendeman SP. Prediction of microclimate pH in poly(lactic-co-glycolic acid) films. J. Am. Chem. Soc. 128, 5384-5390 (2006).
22. Klose D, Siepmann F, Elkharraz K, Siepmann J. PLGA-based drug delivery systems -importance of the type of drug and device geometry. Int. J. Pharm. 354(1-2), 95-103 (2008). (Pubitemid 351410450)
23. Miller RA, Brady JM, Cutright DE. Degradation rates of oral resorbable implants (polylactates and polyglycolates): rate modification with changes in PLA/PGA copolymer ratios. J. Biomed. Mater. Res. 11, 711-719 (1977). (Pubitemid 8159588)
24. Dunne M, Corrigan OI, Ramtoola Z. Influence of particle size and dissolution conditions on the degradation properties of polylactide-co-glucolide particles. Biomaterials 21, 1659-1668 (2000). (Pubitemid 30347308)
25. Perez-Marrero R, Tyler RC. A subcutaneous delivery system for the extended release of leuprolide acetate for the treatment of prostate cancer. Expert Opin. Pharmacother. 5(2), 447-457 (2004). (Pubitemid 38219870)
26. Brodbeck KJ, Pushpala S, McHugh AJ. Sustained release of human growth hormone from PLGA solution depots. Pharm. Res. 16(12), 1825-1829 (1999). (Pubitemid 30040697)
27. Shah NH, Railkar AS, Chen FC, et al. A biodegradable injectable implant for delivering micro and macromolecules using PLGA copolymers. J. Control. Release 27, 139-147 (1993). (Pubitemid 23328982)
28. Graham PD, Brodbeck KJ, McHugh AJ. Phase inversion dynamics of PLGA solutions related to drug delivery. J. Control. Release 58, 233-245 (1999). (Pubitemid 29112894)
29. Brodbeck KJ, DesNoyer JR, McHugh AJ. Phase inversion dynamics of PLGA solutions related to drug delivery -Part II the role of solution thermodynamics and batch-side mass transfer. J. Control. Release 62, 333-344 (1999). (Pubitemid 29476581)
30. Dunn RL, Tipton AJ, Menardi EM. A biodegradable in-situ forming drug delivery system. Proc. Intern. Symp. Control. Release Bioact. Mater. 18, 456-466 (1991).
31. Schoenhammer K, Petersen H, Guethlein F, Goepferich A. Injectable in situ forming depot systems: PEG-DAE as a novel solvent for improved PLGA storage stability. Int. J. Pharm. 371, 33-39 (2009).
32. Schoenhammer K, Petersen H, Guethlein F, Goepferich A. Poly(ethylene glycol)500 dimethylether as a novel solvent for injectable in situ forming depots. Pharm. Res. 26(12), 2568-2577 (2009).
33. Shively ML, Coonts BA, Renner WD, Southard SL, Bennett AT. Physicochemical characterisation of a polymeric injectable implant delivery system. J. Control. Release 33, 237-243 (1995).
34. Astaneh R, Erfan M, Moghimi H, Mobedi H. Changes in morphology of in situ forming PLGA implant prepared by different polymer molecular weight and its effect on release behaviour. J. Pharm. Sci. 98(1), 135-145 (2009).
35. Astaneh R, Nafissi-Varcheh N, Erfan M. Zinc-leuprolide complex: preparation, physicochemical characterisation and release behaviour from in situ forming implant. J. Peptide Sci. 13, 649-654 (2007). (Pubitemid 47570383)
36. Ravivarapu HB, Moyer KL, Dunn RL. Parameters affecting the efficacy of a sustained release polymeric implant of leuprolide. Int. J. Pharm. 194, 181-191 (2000). (Pubitemid 30110680)
37. Jain RA, Rhodes CT, Railkar AM, et al. Controlled release of drugs from a novel injectable in situ formed biodegradable PLGA microsphere system. Pharm. Sci. 1(Suppl. 1), S298 (1998).
38. Luan X, Bodmeier R. Influence of the PLGA type on the leuprolide release from in situ forming microparticle systems. J. Control. Release 110, 266-272 (2006). (Pubitemid 41827479)
39. Luan X, Bodmeier R. In situ forming microparticle system for drug delivery of leuprolide acetate: influence of the formulation and processing parameters. Eur. J. Pharm. Sci. 27, 143-149 (2006). (Pubitemid 41831249)
40. Kranz H, Bodmeier R. A novel in situ forming drug delivery system for controlled parenteral drug delivery. Int. J. Pharm. 332, 107-114 (2007). (Pubitemid 46227772)
41. Okumu F, Dao LN, Fielder PJ, et al. Sustained delivery of human growth hormone from a novel gel system: SABER™. Biomaterials 23, 4353-4358 (2002).
42. Pechenov S, Shenoy B, Yang MX, Basu SK, Margolin AL. Injectable controlled release formulations incorporating protein crystals. J. Control. Release 96, 149-158 (2004). (Pubitemid 38438497)
43. Tae G, Kornfield JA, Hubbell JA. Sustained release of human growth hormone from in situ forming hydrogels using self-assembly of fluoroalkyl-ended poly(ethylene glycol). Biomaterials 26, 5259-5266 (2005). (Pubitemid 40387848)
44. Ruiz-Hornillos J, Henriquez-Santana A, Moreno-Fernandez A, et al. Systemic allergic dermatitis caused by the solvent of Eligard. Contact Dermatitis 61(6), 355-356 (2009).
45. Jeong B, Bae YH, Lee DS, Kim SW. Biodegradable block co-polymers as injectable drug delivery systems. Nature 388, 860-862 (1997). (Pubitemid 27377054)
46. Zentner GM, Rathi R, Shih C, et al. Biodegradable block copolymers for delivery of proteins and water-insoluble drugs. J. Control. Release 72, 203-215 (2001). (Pubitemid 32522358)
47. Chen S, Singh J. Controlled release of growth hormone from thermosensitive triblock copolymer systems: in vitro and in vivo evaluation. Int. J. Pharm. 352, 58-65 (2008). (Pubitemid 351284586)
48. Katakam M, Ravis WR, Banga AK. Controlled release of human growth hormone in rats following parenteral administration of poloxamers gels. J. Control. Release 49, 21-26 (1997). (Pubitemid 27417897)
49. Katakam M, Ravis WR, Golden DL, Banga AK. Controlled release of human growth hormone following subcutaneous administration in dogs. Int. J. Pharm. 152, 53-58 (1997). (Pubitemid 27254961)
50. Chen PC, Park YJ, Chang LC, et al. Injectable microparticle-gel system for prolonged and localised lidocaine release. I. In vitro characterization. J. Biomed. Mater. Res. 70(3), 412-419. (2004).
51. Chen PC, Kohane DS, Park YJ, et al. Injectable microparticle-gel system for prolonged and localised lidocaine release. II. In vivo anesthetic effects. J. Biomed. Mater. Res. 70A, 459-466 (2004). (Pubitemid 39145246)
52. Ricci EJ, Bentley MVLB, Farah M, Bretas RES, Marchettis JM. Rheological characterisation of poloxamers 407 lidocaine hydrochloride gels. Eur. J. Pharm. Sci. 17, 161-167 (2002). (Pubitemid 35248270)
53. Ricci EJ, Lunardi LO, Nanclares DMA, Marchetti JM. Sustained release of lidocaine from poloxamers gels. Int. J. Pharm. 288, 235-244 (2005). (Pubitemid 40038576)
54. Zhang L, Parsons DL, Navarre C, Kompella UB. Development and in vitro evaluation of sustained release poloxamers 407 gel formulations of ceftiofur. J. Control. Release 85, 73-81 (2002). (Pubitemid 35449455)
55. Johnston TP, Punjabi MA, Froelich CJ. Sustained delivery of interleukin-2 from a poloxamers 407 gel matrix following intraperitoneal injection in mice. Pharm. Res. 9(3), 425-434 (1992).
56. Katakam M, Banga AK. Use of poloxamers polymers to stabilise recombinant human growth hormone against various processing stresses. Pharm. Dev. Tech. 2(2), 143-149 (1997). (Pubitemid 28252530)
57. Jiang Z, You Y, Deng XM, Hao JY. Injectable hydrogels of poly(?-caprolactone-co-glycolide)-co-poly(ethylene glycol)-poly(?-caprolactone- co-glycolide) triblock copolymer aqueous solutions. Polymer 48, 4786-4792 (2007). (Pubitemid 47069494)
58. Van de Weert M, Hennink WE, Jiskoot W. Protein instability in poly(lactic-co-glycolic acid) microparticles. Pharm. Res. 17(10), 1159-1167 (2000).
59. Jiang Z, Hao J, You Y, Qun G, Cao W, Deng X. Biodegradable thermogelling hydrogel of P(CL-GL)-PEG-P(CL-GL) triblock copolymer: degradation and drug release behaviour. J. Pharm. Sci. 98(8) 2603-2610 (2009).
60. Jain RA. The manufacturing technologies of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials 21, 2475-2490 (2000).
61. Freitas S, Merkle HP, Gander B. Microencapsulation by solvent extraction/evaporation: reviewing the state of the art of microsphere preparation process technology. J. Control. Release 102, 313-332 (2005). (Pubitemid 40093756)
62. O'Donnell PB, McGinty JW. Preparation of microspheres by the solvent evaporation technique. Adv. Drug Delivery Rev. 28, 25-42 (1997). (Pubitemid 27497672)
63. Sukumar M, Storms SM, De Felippis MR. Non-native intermediate conformational states of human growth hormone in the presence of organic solvents. Pharm. Res. 22(5), 789-796 (2005). (Pubitemid 40768592)
64. Sah H. Protein behaviour at the water/methylene chloride interface. J Pharm. Sci., 88(12), 1320-1325 (1999).
65. Cleland JL, Jones AJS. Stable formulations of recombinant human growth hormone and interferon-g for microencapsulation in biodegradable microspheres. Pharm. Res. 13(10), 1464-1475 (1996). (Pubitemid 26356947)
66. Castellanos IJ, Cruz G, Crespo R, Greibenow K. Encapsulation induced aggregation and loss in activity of g-chymotrypsin and their prevention. J. Control. Release 81, 307-319 (2002). (Pubitemid 34607150)
67. Kim HK, Park TG. Microencapsulation of human growth hormone within biodegradable polyester microspheres: protein aggregation stability and incomplete release mechanism. Biotech. Bioeng. 65(6) 659-667 (1999).
68. Perez C, Griebenow K. Effects of salts on lysozyme stability at the water-oil interface and upon encapsulation in PLGA microspheres. Biotech. Bioeng. 82(7) 825-832 (2003). (Pubitemid 36604454)
69. Perez C, Griebenow K. Improved activity and stability of lysozyme at the water/CH2Cl2 interface: enzyme unfolding and aggregation and its prevention by polyols. J. Pharm. Pharmacol. 53, 1217-1226 (2001). (Pubitemid 32904016)
70. Van de Weert M, Hoechstetter J, Hennink WE, Crommelin DJA. The effect of a water/organic solvent interface on the structural stability of lysozyme. J. Control. Release 68, 351-359 (2000).
71. Carrasquillo KG, Carro JCA, Alejandro A, Toro DD, Greibenow K. Reduction of structural perturbations in bovine serum albumin by non-aqueous microencapsulation. J. Pharm. Pharmacol. 53, 115-120 (2001). (Pubitemid 32123707)
72. Pérez C, De Jesus P, Griebenow K. Preservation of lysozyme structure and function upon encapsulation and release from poly(lactic-co- glycolic) acid microspheres prepared by the water-in-oil-in-water method. Int. J. Pharm. 248, 193-206 (2002). (Pubitemid 35345154)
73. Cleland JL, Mac A, Boyd B, et al. The stability of recombinant human growth hormone in poly(lactic-co-glycolic acid) PLGA microspheres. Pharm. Res. 14(4) 420-425 (1997). (Pubitemid 27204998)
74. Cleland JL, Duenas E, Daugherty A, et al. Recombinant human growth hormone poly(lactic-co-glycolic acid) (PLGA) microspheres provide a long lasting effect. J. Control. Release 49, 193-205 (1997). (Pubitemid 28020273)
75. Cleland JL, Johnson O, Putney S, Jones AJS. Recombinant human growth hormone poly(lactic-co-glycolic acid) microsphere formulation development. Adv. Drug Delivery Rev. 28, 71-84 (1997). (Pubitemid 27497674)
76. Kwak HH, Shim WS, Choi MK, et al. Development of a sustained release recombinant human growth hormone formulation. J. Control. Release 137, 160-165 (2009).
77. Castellanos IJ, Flores G, Griebenow K. Effect of cyclodextrins on ?-chymotrypsin stability and loading in PLGA microspheres upon s/o/w emulsion. J. Pharm. Sci. 95 (4) 849-858 (2006).
78. Quaglia F, De Rosa G, Granata E, et al. Feeding liquid, non-ionic surfactant and cyclodextrin affect the properties of insulin-loaded poly(lactide-co-glycolide) microspheres prepared by spray drying. J. Control. Release 86, 267-278 (2003). (Pubitemid 36084275)
79. De Rosa G, Larobina D, La Rotonda MI, et al. How cyclodextrin incorporation affects the properties of protein-loaded PLGA-based microspheres: the case of insulin/hydroxypropyl-b-cyclodextrin. J. Control. Release 102, 71-83 (2005). (Pubitemid 40093777)
80. Bezemer JM, Radersma R, Grijpma DW, et al. Zero-order release of lysozyme from poly(ethylene glycol)/poly(butylenes terephthalate matrices. J. Control. Release 64, 179-192 (2000). (Pubitemid 30035318)
81. Bezemer JM, Radersma R, Grijpma DW, Dijkstra PJ, van Blitterswijk CA, Feijen J. Microspheres for protein delivery prepared from amphiphilic multibock copolymers 1 influence of preparation techniques on particle characteristics and protein delivery. J. Control. Release 67, 233-248 (2000). (Pubitemid 30303838)
82. Van Dijkhuizen-Radersma R, Nicolas HM, van de Weert M, et al. Stability aspects of salmon calcitonin entrapped in poly(ether ester) sustained release systems, Int. J. Pharm. 248, 229-237 (2002). (Pubitemid 35341425)
83. Griebenow K, Kilbanov AM. On protein denaturation in aqueous-organic mixtures but not in pure organic solvents. J. Am. Chem. Soc. 118(47), 11695-11700 (1996). (Pubitemid 26417457)
84. Carrasquillo KG, Stabley AM, Aponte-Carro JC, et al. Non-aqueous encapsulation of excipient-stabilised spray-freeze dried BSA into poly(lactide-co-glycolide) microspheres results in release of native protein. J. Control. Release 76, 199-208 (2001). (Pubitemid 32913430)
85. Petit DK, Lawter JR, Huang WJ, et al. Characterisation of poly(glycolide-co-d,l-lactide)/poly(D,L-lactide) microspheres for controlled release of GM-CSF. Pharm. Res. 14(10), 1422-1430 (1997). (Pubitemid 27481074)
86. Constantino HR, Johnson OL, Zale SE. Relationship between encapsulated drug particle size and initial release of recombinant human growth hormone from biodegradable microspheres. J. Pharm Sci. 93(10), 2624-2634 (2004). (Pubitemid 39319445)
87. Takada S, Yamagata Y, Misaki M, Taira K, Kurokawa T. Sustained release of human growth hormone from microcapsules prepared by a solvent evaporation technique. J. Control. Release 88, 229-242 (2003). (Pubitemid 36287340)
88. Castellanos IJ, Carrasquillo KG, Lopez JDJ, Alvarez M, Griebenow K. Encapsulation of bovine serum albumin in poly(lactide-co-glycolide) microspheres by the solid-in-oil-in-water technique. J. Pharm. Pharmacol. 53, 167-178 (2001). (Pubitemid 32156509)
89. Wang J, Chua KM, Wang CH. Stabilisation and encapsulation of human immunoglobulin G into biodegradable microspheres. J. Col. Inter. Sci. 271, 92-101 (2004). (Pubitemid 38147608)
90. Kim TK, Burgess DJ. Pharmacokinetic characterisation of 14C-vascular endothelial growth factor controlled release microspheres using a rat model. J. Pharm. Pharmacol. 54, 897-905 (2002). (Pubitemid 34763833)
91. Zhu G, Mallery SR, Schwendeman SP. Stabilisation of proteins encapsulated in injectable poly(lactide-co-glycolide). Nature Biotech. 18, 52-57 (2000). (Pubitemid 30041172)
92. Kang J, Schwendeman SP. Comparison of the effects of Mg(OH)2 and sucrose on the stability of bovine serum albumin encapsulated in injectable poly(D,L-lactide-co-glycolide) implants. Biomaterials 23, 239-245 (2002). (Pubitemid 33041359)
93. Castellanos IJ, Crespo R, Griebenow K. Poly(ethylene glycol) as stabiliser and emulsifying agent: a novel stabilisation approach preventing aggregation and inactivation of proteins upon encapsulation in bioerodible polyester microspheres. J. Control. Release 88, 135-145 (2003). (Pubitemid 36173959)
94. Castellanos IJ, Griebenow K. Improved ?-chymotrypsin stability upon encapsulation in PLGA microspheres by solvent replacement. Pharm. Res. 20(11), 1873-1880 (2003). (Pubitemid 37449464)
95. Morita T, Sakamura Y, Horikiri Y, Suzuki T, Yoshino H. Protein encapsulation into biodegradable microspheres by a novel s/o/w emulsion method using poly(ethylene glycol) as a protein micronisation adjuvant. J. Control. Release 69, 435-444 (2000).
96. Morita T, Horikiri Y, Suzuki T, Yoshino H. Applicability of various amphiphilic polymers to the modification of protein release kinetics from biodegradable reservoir-type microspheres. Eu. J. Pharm. Biopharm. 51, 45-53 (2001). (Pubitemid 32037041)
97. Takada S, Yamagata Y, Misaki M, Taira K, Kurokawa T. Sustained release of human growth hormone from microcapsules prepared by a solvent evaporation technique. J. Control. Release 88, 229-242 (2003). (Pubitemid 36287340)
98. Takada S, Kurokawa T, Misaki M, Taira K, Yamagata Y. A new animal model for the evaluation of long-term growth rate over one month by rhGH/PLGA microcapsule formulations. J. Pharm. Pharmacol. 55, 951-961 (2003). (Pubitemid 36916685)
99. Takenaga M, Yamaguchi Y, Kitagawa A, Ogawa Y, Mizushima Y, Igarashi R. A novel sustained release formulation of insulin with dramatic reduction in rapid release. J. Control. Release 79, 81-91 (2002). (Pubitemid 34164163)
100. Yamaguchi Y, Takenaga M, Kitagawa A, Ogawa Y, Mizushima Y, Igarashi R. Insulin-loaded biodegradable PLGA microcapsules: initial burst release controlled by hydrophilic additives. J. Control. Release 81, 235-249 (2002). (Pubitemid 34607145)
101. Takenaga M, Yamaguchi Y, Kitagawa A, et al. Optimum formulation for sustained release insulin. Int. J. Pharm. 271, 85-94 (2004). (Pubitemid 38210087)
102. Takenaga M, Yamaguchi Y, Kitagawa A, Ogawa Y, Mizushima Y, Igarashi R. A novel insulin formulation can keep providing steady levels of insulin for much longer periods in vivo. J. Pharm. Pharmacol. 54, 1189-1194 (2002).
103. Tracy MA. Development and scale-up of a microsphere protein delivery system. Biotechnol. Prog. 14, 108-115 (1998).
104. Johnson OL, Cleland JL, Lee HJ, et al. A month-long effect from a single injection of microencapsulated human growth hormone. Nature Med. 2, 795-799 (1996). (Pubitemid 26225096)
105. Johnson OL, Jaworowicz W, Cleland JL, et al. The stabilisation and encapsulation of human growth hormone into biodegradable microspheres. Pharm. Res. 14(6), 730-735 (1997). (Pubitemid 27281666)
106. Lee HJ, Riley G, Johnson O, et al. In vivo characterisation of sustained release formulations of human growth hormone. J. Pharmacol. Exp. Thera. 281(3), 1431-1439 (1997). (Pubitemid 27258404)
107. Reiter EO, Attie KM, Moshang T, et al. A multicenter study of the efficacy and safety of sustained release GH in the treatment of naive pediatric patients with GH deficiency. J. Clin. Endo. Met. 86(10), 4700-4706 (2001). (Pubitemid 33020508)
108. Kemp SF, Fielder PJ, Attie KM, et al. Pharmacokinetic and pharmacodynamic characteristics of a long acting growth hormone (GH) preparation (Nutropin® Depot) in GH-deficient children. J. Clin. Endo. Met. 89(7), 3234-3240 (2004). (Pubitemid 38951887)
109. Howdle SM, Watson MS, Whitaker MJ, et al. Supercritical fluid mixing: preparation of thermally sensitive polymer composites containing bioactive materials. Chem. Commun. 2001, 109-110 (2001). (Pubitemid 32094839)
110. Watson MS, Whitaker MJ, Howdle SM, Shakesheff KM. Incorporation of proteins into polymer materials by a novel supercritical fluid processing method. Adv. Mater. 14(24), 1802-1804 (2002).
111. Hao J, Whitaker MJ, Wong B, Serhatkulu G, Shakesheff KM, Howdle SM. Plasticization and spraying of poly(d,l-lactic acid) using supercritical carbon dioxide: control of particle size. J. Pharm. Sci. 93(4), 1083-1090 (2004). (Pubitemid 38420418)
112. Hao J, Whitaker MJ, Wong B, Serhatkulu G, Shakesheff KM, Howdle SM. Supercritical fluid assisted melting of poly(ethylene glycol): a new solvent-free route to microparticles. J. Mater. Chem. 15, 1148-1153 (2005). (Pubitemid 40449477)
113. Whitaker MJ, Hao J, Davies OR, et al. The production of protein-loaded microparticles by supercritical fluid enhanced mixing and spraying. J. Control. Release 101, 85-92 (2005). (Pubitemid 39600974)
114. Jordan F, Naylor A, Kelly CA, Howdle SM, Lewis A, Illum L. Sustained release hGH microsphere formulation produced by a novel supercritical fluid technology: in vivo studies. J. Control. Release 141, 153-160 (2010).
115. Reslow M, Jonsson M, Laakso T. Sustained release of human growth hormone from PLG-coated starch microspheres. Drug Del. Sys. Sci. 2, 103-109 (2002).
116. Jostel A, Mukherjee A, Alenfall J, Smethurst L, Shalet AM. A new sustained release preparation of human growth hormone and its pharmacokinetic, pharmacodynamic and safety profile. Clin. Endo. 62, 623-627 (2005). (Pubitemid 40646733)
117. Stenekes RJH, Franssen O, van Brommel EMG, Crommelin DJA, Hennink WE. The preparation of dextran microspheres in an all-aqueous system: effect of formulation parameters on particle characteristics. Pharm. Res. 15(4), 557-561 (1998). (Pubitemid 28214948)
118. Franssen O, Vandervennet L, Roders P, Hennink WE. Degradable dextran hydrogels: controlled release of a model protein from cylinders and microspheres. J. Control. Release 60, 211-221 (1999). (Pubitemid 29335947)
119. Vlugt-Wensink KDF, Meijer YJ, van Steenbergen MJ, et al. Effect of excipients on the encapsulation efficiency and release of human growth hormone from dextran microspheres. Eur. J. Pharm. Biopharm. 67, 589-596 (2007). (Pubitemid 47576616)
120. Vlugt-Wensink KDF, de Vreuh R, Gresnigt MG, et al. Preclinical and clinical in vitro in vivo correlation of an hGH dextran microsphere formulation. Pharm. Res. 24(12), 2239-2248 (2007). (Pubitemid 350060716)
121. Moore WV, Leppert P. Role of aggregated human growth hormone (hGH) in development of antibodies to hGH. J. Clin. Endo. Met. 51(4), 691-697 (1980). (Pubitemid 10024715)
122. Woo BH, Jiang G, Jo YW, DeLuca PP. Preparation and characterisation of a composite PLGA and poly(acryloyl hydroxyethyl starch) microsphere system for protein delivery. Pharm. Res. 18(11), 1600-1606 (2001). (Pubitemid 33022417)
123. Capan Y, Jiang G, Giovagnoli S, Na KH, DeLuca PP. Preparation and characterisation of poly(d,l-lactide-co-glycolide) microspheres for controlled release of human growth hormone. AAPS PharmSciTech 4(2) 1-10 (2003).
124. Jiang G, Qiu W, DeLuca PP. Preparation and in vitro-in vivo evaluation of insulin loaded poly(acryloyl hydroxyethyl starch)-PLGA composite microspheres. Pharm. Res. 20(3), 452-459 (2003). (Pubitemid 36288377)
125. Schoubben A, Blasi P, Giovagnoli S, Perioli L, Rossi C, Ricci M. Novel composite microparticles for protein stabilisation and delivery. Eur. J. Pharm. Sci. 36, 226-234 (2009).
126. Johansen P, Tamber H, Merkle P, Gander B. Diphtheria and tetanus toxoid microencapsulation into conventional and end-group alhylated PLA/PLGAs. Eu. J. Pharm. Biopharm. 47, 193-201 (1999). (Pubitemid 29257878)
127. Agrawal CM, Athanasiou KA. Technique to control pH in vicinity of biodegrading PLA-PLGA implants. J. Biomed. Mater. Res. 38, 105-114 (1997). (Pubitemid 27233098)
128. Shao PG, Bailey LC. Stabilisation of pH-induced degradation of porcine insulin in biodegradable polyester microspheres. Pharm. Dev. Technol. 4, 633-642 (1999). (Pubitemid 29536085)
129. Kim HK, Park TG. Comparative study on sustained release of human growth hormone from semi-crystalline poly(l-lactic acid) and amorphous poly(d,l-lactic-co-glycolic acid) microspheres: morphological effect on protein release. J. Control. Release 98, 115-125 (2004). (Pubitemid 38881612)
130. Kim HK, Chung HJ, Park TG. Biodegradable polymeric microspheres with open/closed pores for sustained release of human growth hormone. J. Control. Release 112, 167-174 (2006).
131. Bae SE, Son JS, Park K, Han DK. Fabrication of covered porous PLGA microspheres using hydrogen peroxide for controlled drug delivery and regenerative medicine. J. Control. Release 133, 37-43 (2009).
132. Lucke A, Kiermaier J, Gopferich A. Peptide acylation by poly(?-hydroxy esters). Pharm. Res. 19(2), 175-181 (2002).
133. Murty SB, Goodman J, Thanoo BC, DeLuca PP. Identification of chemically modified peptide from poly(lactide-co-glycolide) microspheres under in vitro release conditions. AAPS PharmSciTech 4(4), E50 (2003).
134. Murty SB, Thanoo BC, Wei Q, DeLuca PP Impurity formation studies with peptide loaded polymeric microspheres Part I. In vivo evaluation. Int. J. Pharm. 297, 50-61 (2005). (Pubitemid 40720265)
135. Murty SB, Dong HN, Thanoo BC, DeLuca PP. Impurity formation studies with peptide loaded polymeric microspheres Part II. In vitro evaluation. Int. J. Pharm. 297, 62-72 (2005). (Pubitemid 40720266)
136. Ibrahim MA, Ismail A, Fetouch MI, Gopferich A. Stability of insulin during the erosion of poly(lactic acid) and poly(lactic-co-glycolic acid) microspheres. J. Control. Release 106, 241-252 (2005). (Pubitemid 41187434)
137. Lam XM, Duenas ET, Cleland JL. Encapsulation and stabilisation of nerve growth factor into poly(lactic-co-glycolic) acid microspheres. J. Pharm. Sci. 90(9), 1356-1365 (2001). (Pubitemid 32867984)
138. Tsai T, Mehta RC, DeLuca PP. Adsorption of peptides to poly(D,L-lactide-co-glycolide):1 effect of physical factors. Int. J. Pharm. 127, 31-42 (1996). (Pubitemid 26069151)
139. Tsai T, Mehta RC, DeLuca PP. Adsorption of peptides to poly(d,l -lactide-co-glycolide):2 effect of solution properties on the adsorption. Int. J. Pharm. 127, 43-52 (1996). (Pubitemid 26069152)
140. Calis S, Jeyanthi R, Tsai T, Mehta RC, DeLuca PP. Adsorption of salmon calcitonin to PLGA microspheres. Pharm. Res. 12(7), 1072-1076 (1995).
141. Mehta RC, Jeyanthi R, Calis S, Thanoo BC, Burton KW, DeLuca PP. Biodegradable microspheres as depot system for parenteral delivery of peptide drugs. J. Control. Release 29, 375-384 (1994).
142. Jiang G, Woo BH, Kang F, Singh J, DeLuca PP. Assessment of protein release kinetics, stability and protein polymer interaction of lysozyme encapsulated poly(d,l -lactide-co-glycolide) microspheres. J. Control. Release 79, 137-145 (2002). (Pubitemid 34164167)
143. Jiang W, Schwendeman SP. Stabilisation and controlled release of bovine serum albumin encapsulated in poly(d,l lactide) and poly(ethylene glycol) microsphere blends. Pharm. Res. 18(6), 878-885 (2001). (Pubitemid 32783527)
144. Diaz RV, Soriano I, Delgado A, Llabres M, Evora C. Effect of surfactant agents on the release of 125I-bovine calcitonin from PLGA microspheres: in vitro-in vivo study. J. Control. Release 43, 59-64 (1997). (Pubitemid 26393608)
145. De Rosa G, Iommelli R, La Rotonda MI, Miro A, Quaglia F. Influence of the co-encapsulation of different non-ionic surfactants on the properties of PLGA insulin-loaded microspheres. J. Control. Release 69, 283-295 (2000).
146. Chan YP, Meyrueix R, Kravtzoff R, Nicolas F, Lundstrom K. Review on Medusa®: a polymer-based sustained release technology for protein and peptide drugs. Expert Opin. Drug Del. 4(4), 441-451 (2007). (Pubitemid 47249141)
147. Eligard prescribing information http://products.sanofi-aventis.us/ eligard/eligard-75.html
148. OctoPlus press release, June 2009 http://observer.OctoPlus.nl/index.cfm/ OctoPlus/news-centre/news-releases/index. cfm?news-article=OctoPlus-licensee- biolex-completes-patient-enrollment-in-phase-iib-study-with-locteron
149. Genentech press release, 1 June 2004 www.gene.com/gene/news/press- releases/display.do?method=detail&id=7447
150. Flamel Technologies press release, 18 December 2009 www.flamel.com/ pressReleases/2009.shtml